Status: Not yet recruiting
Exploratory Study on Toripalimab and Anlotinib Combined With Standard Chemotherapy for Refractory Dermatofibrosarcoma Protuberans
This study aims to evaluate the efficacy and safety of toripalimab and anlotinib hydrochloride combined with standard chemotherapy in patients with refractory dermatofibrosarcoma protuberans (DFSP) resistant to imatinib therapy, and to provide evidence for the exploration of DFSP treatment.
Participants needed: 20
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Yanjie Zhang, MDUpdated: Jun 16, 2026
Eligibility criteria
Male or female patients aged ≥18 years. [+12]
Spinal cord compression, leptomeningeal disease, or clinically active central ne... [+7]